{"id":239,"date":"2026-11-03T00:17:22","date_gmt":"2026-11-03T00:17:22","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=239"},"modified":"2026-11-03T00:20:42","modified_gmt":"2026-11-03T00:20:42","slug":"triple-combination-therapy-against-%ce%b2-lactamase-mediated-resistance-%ce%b2-lactam-sbl-inhibitor-mbl-agent-target-strategy-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/triple-combination-therapy-against-%ce%b2-lactamase-mediated-resistance-%ce%b2-lactam-sbl-inhibitor-mbl-agent-target-strategy-intelligence-dossier\/","title":{"rendered":"Triple Combination Therapy Against \u03b2-Lactamase-Mediated Resistance: \u03b2-Lactam + SBL Inhibitor + MBL Agent \u2014 Target &#038; Strategy Intelligence Dossier"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">The problem: resistance now travels in pairs<\/h2>\n\n\n\n<p>The &#8220;silent pandemic&#8221; of antimicrobial resistance (AMR) was linked to <strong>4.95 million deaths in 2019<\/strong>, with a projected 10 million\/year by 2050. For the WHO&#8217;s critical Gram-negative threats&#8201;&#8212;&#8201;<em>Enterobacterales<\/em> and <em>Acinetobacter baumannii<\/em>&#8201;&#8212;&#8201;the proximate cause is the <strong>\u03b2-lactamase<\/strong>: an enzyme that hydrolyses the \u03b2-lactam ring at the heart of our most reliable antibiotic class.<\/p>\n\n\n\n<p>The clinically awkward reality is that these enzymes no longer come one at a time. Surveillance (ATLAS) shows meropenem-resistant isolates carrying <strong>MBLs in 36%, KPC in 25%, and OXA-48-like in 24%<\/strong>, with the <strong>NDM&#8201;+&#8201;OXA-48-like<\/strong> pairing emerging as the dominant driver in <em>Enterobacterales<\/em>. Two mechanistic classes are in play simultaneously:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Serine \u03b2-lactamases (SBLs)<\/strong>&#8201;&#8212;&#8201;Ambler classes A\/C\/D; a catalytic serine acylates and hydrolyses the \u03b2-lactam. Many <strong>SBL inhibitors (SBLIs)<\/strong> are marketed.<\/li><li><strong>Metallo-\u03b2-lactamases (MBLs)<\/strong>&#8201;&#8212;&#8201;Ambler class B; a <strong>di-Zn<sup>2+<\/sup><\/strong> centre activates a bridging hydroxide. <strong>No MBL inhibitor is FDA-approved<\/strong>, and only a handful are in late-stage trials.<\/li><\/ul>\n\n\n\n<p>Inhibit one class and the other still shreds your \u03b2-lactam. This <em>Perspective<\/em> from Naicker, Silva and co-workers (UKZN&#8201;\/&#8201;Karolinska&#8201;\/&#8201;UFPA) argues for a pragmatic, <strong>immediately deployable<\/strong> answer: <strong>triple combination therapy<\/strong>&#8201;&#8212;&#8201;a \u03b2-lactam antibiotic&#8201;+&#8201;an SBLI&#8201;+&#8201;an MBL-targeting agent&#8201;&#8212;&#8201;as a bridge while dedicated dual-&#8203;\/MBL-inhibitors mature.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The strategy: three mechanisms, one regimen<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2150\" height=\"1382\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept.png\" alt=\"Triple-combination logic: \u03b2-lactam + SBL inhibitor + MBL-targeting agent, with the serine vs di-zinc hydrolysis mechanisms. Concept figure by Astinova Bio Labs.\" class=\"wp-image-235\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept.png 2150w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept-300x193.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept-1024x658.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept-768x494.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept-1536x987.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_concept-2048x1316.png 2048w\" sizes=\"auto, (max-width: 2150px) 100vw, 2150px\" \/><figcaption class=\"wp-element-caption\">Triple-combination logic: \u03b2-lactam + SBL inhibitor + MBL-targeting agent, with the serine vs di-zinc hydrolysis mechanisms. Concept figure by Astinova Bio Labs.<\/figcaption><\/figure>\n\n\n\n<p>The logic is additive coverage. The <strong>\u03b2-lactam<\/strong> still delivers the lethal PBP-targeting hit; the <strong>SBLI<\/strong> shields it from serine enzymes; and an <strong>MBL-targeting agent<\/strong> closes the class B gap&#8201;&#8212;&#8201;either a dedicated inhibitor or, cleverly, an <strong>MBL-stable \u03b2-lactam<\/strong> (aztreonam) that simply isn&#8217;t a substrate for the zinc machinery. The distinction the authors draw between <strong>dual-\u03b2-lactamase inhibitors<\/strong> (one molecule hitting SBLs <em>and<\/em> MBLs) and <strong>dual-target enhancers<\/strong> (\u03b2-lactamase inhibition <em>plus<\/em> direct PBP binding) matters for how each agent is partnered.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The chemical landscape: four scaffolds doing the work<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2016\" height=\"2316\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape.png\" alt=\"The \u03b2-lactamase inhibitor landscape: \u03b2-lactam-based SBLIs, DBO agents, bicyclic boronate dual inhibitors, and \u03b2-lactam partners. Structures drawn with RDKit by Astinova Bio Labs.\" class=\"wp-image-234\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape.png 2016w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape-261x300.png 261w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape-891x1024.png 891w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape-768x882.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape-1337x1536.png 1337w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_landscape-1783x2048.png 1783w\" sizes=\"auto, (max-width: 2016px) 100vw, 2016px\" \/><figcaption class=\"wp-element-caption\">The \u03b2-lactamase inhibitor landscape: \u03b2-lactam-based SBLIs, DBO agents, bicyclic boronate dual inhibitors, and \u03b2-lactam partners. Structures drawn with RDKit by Astinova Bio Labs.<\/figcaption><\/figure>\n\n\n\n<p>The medicinal-chemistry story is a progression of warheads, and it maps cleanly onto four classes:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u03b2-Lactam-based SBLIs<\/strong>&#8201;&#8212;&#8201;clavulanic acid (1972), tazobactam, and the 2024 approval <strong>enmetazobactam<\/strong> (a single triazolium methyl on tazobactam that sharpens ESBL coverage with cefepime). Classic covalent &#8220;suicide&#8221; inhibitors&#8201;&#8212;&#8201;but a shared \u03b2-lactam pharmacophore means \u03b2-lactamases eventually learn to hydrolyse them too.<\/li><li><strong>Diazabicyclooctanones (DBOs)<\/strong>&#8201;&#8212;&#8201;<strong>avibactam<\/strong> is the reversible-covalent SBLI half of the hero combination below; <strong>zidebactam<\/strong> and <strong>nacubactam<\/strong> are <em>dual-target enhancers<\/em> that add high-affinity <strong>PBP2<\/strong> binding to their class A\/C inhibition (both in Phase 3).<\/li><li><strong>Bicyclic boronates<\/strong>&#8201;&#8212;&#8201;the dual-\u03b2-lactamase inhibitors: <strong>taniborbactam<\/strong>, <strong>xeruborbactam<\/strong>, and <strong>KSP-1007<\/strong>. Fusing a second ring onto the vaborbactam-type boron orients the warhead into the shallow MBL groove, letting one molecule trap <em>both<\/em> enzyme classes. Xeruborbactam&#8217;s <strong>cyclopropyl<\/strong> rigidifies the scaffold and extends borylation to SME-1; KSP-1007 covers Ambler A&#8211;D.<\/li><li><strong>\u03b2-Lactam partners &amp; the anaerobic cap<\/strong>&#8201;&#8212;&#8201;<strong>aztreonam<\/strong> (MBL-stable monobactam), <strong>meropenem<\/strong>&#8203;\/cefepime, and <strong>metronidazole<\/strong>.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The binding rationale: different warhead chemistry for each enzyme<\/h2>\n\n\n\n<p>Two real co-crystal structures tell the whole mechanistic story.<\/p>\n\n\n\n<p>On the <strong>serine<\/strong> side, avibactam&#8217;s sulfonamide-activated urea is attacked by the catalytic serine to form a stable, slowly-reversible carbamoyl-enzyme&#8201;&#8212;&#8201;the drug sits on <strong>Ser70<\/strong>, blocking turnover of the partner \u03b2-lactam.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"945\" height=\"769\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_avibactam_4hbu.png\" alt=\"Avibactam covalently bound to catalytic Ser70 of CTX-M-15 serine \u03b2-lactamase (PDB 4HBU). Rendered by Astinova Bio Labs with 3Dmol.js.\" class=\"wp-image-236\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_avibactam_4hbu.png 945w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_avibactam_4hbu-300x244.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_avibactam_4hbu-768x625.png 768w\" sizes=\"auto, (max-width: 945px) 100vw, 945px\" \/><figcaption class=\"wp-element-caption\">Avibactam covalently bound to catalytic Ser70 of CTX-M-15 serine \u03b2-lactamase (PDB 4HBU). Rendered by Astinova Bio Labs with 3Dmol.js.<\/figcaption><\/figure>\n\n\n\n<p>On the <strong>metallo<\/strong> side, there is no serine to trap. A boronate must instead engage the <strong>di-zinc<\/strong> centre directly: taniborbactam&#8217;s boron adopts the tetrahedral, hydroxide-bound geometry that mimics the high-energy hydrolysis intermediate and bridges <strong>Zn1&#8203;\/Zn2<\/strong> in NDM-1. This is exactly why boronates can span SBLs <em>and<\/em> MBLs&#8201;&#8212;&#8201;and why first-generation boronates remain structurally precarious.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"945\" height=\"769\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_taniborbactam_6rmf.png\" alt=\"Taniborbactam boronate bridging the di-zinc centre of NDM-1 metallo-\u03b2-lactamase (PDB 6RMF). Rendered by Astinova Bio Labs with 3Dmol.js.\" class=\"wp-image-237\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_taniborbactam_6rmf.png 945w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_taniborbactam_6rmf-300x244.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/triplecombo_taniborbactam_6rmf-768x625.png 768w\" sizes=\"auto, (max-width: 945px) 100vw, 945px\" \/><figcaption class=\"wp-element-caption\">Taniborbactam boronate bridging the di-zinc centre of NDM-1 metallo-\u03b2-lactamase (PDB 6RMF). Rendered by Astinova Bio Labs with 3Dmol.js.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">The clinical milestone: Emblaveo (2025)<\/h2>\n\n\n\n<p>The paradigm proof is <strong>aztreonam&#8211;avibactam (Emblaveo)<\/strong>&#8201;&#8212;&#8201;not a single dual molecule but <strong>two agents co-formulated<\/strong>: avibactam neutralises the co-produced SBLs that would otherwise destroy aztreonam, while aztreonam itself slips past the MBLs. <em>In vitro<\/em>, the combination inhibited <strong>99.6% of CRE isolates<\/strong> (including <strong>100% of MBL-producers<\/strong>) across Europe, Asia-Pacific and Latin America. In <strong>2025 the FDA approved Emblaveo with metronidazole<\/strong> for complicated intra-abdominal infections (cIAI) in adults with limited options&#8201;&#8212;&#8201;a <em>bona fide<\/em> triple regimen (anaerobic cover&#8201;+&#8201;SBL inhibition&#8201;+&#8201;MBL-stable \u03b2-lactam).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Zero approved MBL inhibitors<\/strong> is the defining gap in Gram-negative therapy. Taniborbactam&#8201;&#8212;&#8201;once the great MBLI hope&#8201;&#8212;&#8201;was <strong>rejected by the FDA (2024)<\/strong> on PK&#8203;\/tissue-distribution grounds and has shown early resistance via single NDM&#8203;\/VIM substitutions. Enzymatic potency does not absolve a candidate of its physicochemical responsibilities.<\/li><li><strong>Triple combination therapy is deployable today<\/strong> from individually approved agents, buying time for dedicated MBLIs and dual inhibitors to mature. It is a bridge, not an endpoint.<\/li><li>For the medicinal chemist, the take-home is <strong>scaffold-level<\/strong>: covering both SBLs and MBLs is a <em>geometry and warhead<\/em> problem (serine-acylating DBO vs. zinc-bridging boronate), compounded by the usual permeability&#8203;\/efflux&#8203;\/PK gauntlet in Gram-negatives.<\/li><\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>Reference &amp; image credit:<\/strong> Reddy, N.; Silva, J.&#8201;R.&#8201;A.; Arvidsson, P.&#8201;I.; Kruger, H.&#8201;G.; Govender, T.; Naicker, T. &#8220;Triple Combination Therapy: A Promising Path Forward against \u03b2-Lactamase-Mediated Resistance.&#8221; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>, <em>69<\/em>, 23075&#8211;23091. DOI: <a href=\"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c00399\">10.1021\/acs.jmedchem.6c00399<\/a>. Published <strong>open access under a CC-BY 4.0 license<\/strong>, &#169; 2026 The Authors, published by the American Chemical Society. All structures, the concept&#8203;\/mechanism figure, and both binding-mode renders (avibactam&#8211;CTX-M-15, <strong>PDB 4HBU<\/strong>; taniborbactam&#8211;NDM-1, <strong>PDB 6RMF<\/strong>) were generated from scratch by Astinova Bio Labs (RDKit&#8201;+&#8201;3Dmol.js)&#8201;&#8212;&#8201;no paper figures were reused.<\/p>\n\n\n\n<p><em>Astinova Bio Labs designs and makes molecules like these&#8201;&#8212;&#8201;scaffold design, original scheme&#8203;\/structure drawing, and structure-based binding analysis. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your target.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Why no single inhibitor fixes \u03b2-lactamase-mediated AMR \u2014 and how triple combination therapy (\u03b2-lactam + SBL inhibitor + MBL-targeting agent) bridges the gap. The inhibitor landscape, the serine vs di-zinc mechanisms, and the FDA-approved aztreonam\u2013avibactam (Emblaveo) milestone, with original structures and binding renders.<\/p>\n","protected":false},"author":1,"featured_media":233,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[65,69,70,55,72,47,67,68,71,66],"class_list":["post-239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-antimicrobial-resistance","tag-avibactam","tag-boronate-inhibitors","tag-dual-inhibitor","tag-gram-negative","tag-infectious-disease","tag-metallo--lactamase","tag-ndm-1","tag-triple-combination-therapy","tag--lactamase"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=239"}],"version-history":[{"count":2,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/239\/revisions"}],"predecessor-version":[{"id":241,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/239\/revisions\/241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/233"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}